Contact | Sitemap | About Medicines Research Responsibility News Investors Careers Corporate History Timeline Home / About / Corporate History Timeline Senior Management Worldwide Operations Ethics Business Conduct Business Partnerships Corporate History Timeline Share 2017 July 2017 The U.S. Food and Drug Administration approves Vosevi™, the first pan-genotypic single tablet regimen for adults with chronic hepatitis C infection who failed certain direct-acting antiviral regimens. 2016 November 2016 The U.S. Food and Drug Administration approves Vemlidy®, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. June 2016 The U.S. Food and Drug Administration approves Epclusa®, the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. April 2016 The U.S. Food and Drug Administration approves Descovy®, a fixed-dose combination for HIV-1 infection. Gilead acquires Nimbus Apollo, Inc., a wholly-owned subsidiary of Cambridge, Massachusetts-based Nimbus Therapeutics, and its Acetyl-CoA Carboxylase (ACC) inhibitor program. March 2016 The U.S. Food and Drug Administration approves Odefsey®, a complete once-daily, single tablet regimen for HIV-1 infection. 2015 November 2015 The U.S. Food and Drug Administration approves Genvoya®, a complete once-daily, single tablet regimen for HIV-1 infection. May 2015 Gilead acquires Copenhagen, Denmark-based EpiTherapeutics ApS. 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1992 1991 1990 1987 About Gilead Senior Management Worldwide Operations Ethics Business Conduct Business Partnerships Corporate History Timeline Research Pipeline Clinical Trials Investigator Sponsored Research Medicines Request Information Consumer Product Safety Authorized Distributors of Record Product Approval Timeline Responsibility U.S. Patient Access Developing World Access Corporate Contributions Policy Perspectives Gilead Foundation News Press Releases Events Media FAQs Fact Sheets Media Inquiries Investors Recent News Corporate Governance Stock Information Financial Information SEC Filings Shareholder Center Annual Reports Email Alerts Investor FAQs Investor Contacts Investor Disclaimer Careers Pipeline Our Values Developing-World-Access Corporate-Contributions U.S. Benefits © 2009-2016 Gilead. All rights reserved. Terms of Use | Privacy Statements Product images shown do not represent actual size.